May has been a partner in our corporate department since 2016. Having first obtained a degree in genetics, she worked in the Department of Medicine and Therapeutics of the Chinese University of Hong Kong for eight years, where she was involved primarily in medical research and clinical drug trials with a focus on the hepatitis B virus. She then went on to read law and obtained her law degree from the University of London in 2005. After joining the firm as a trainee in 2006, she qualified as a solicitor in Hong Kong in 2008 and has been with the firm since that time.
As a partner, May’s practice is focused on mergers and acquisitions, private equity work, initial public offerings, corporate reorganisations, public company privatisations and general commercial work for private and publicly listed companies in Hong Kong. Her background in life sciences stood her in good stead as a member of the team advising the Hong Kong Stock Exchange in the drafting of the new chapters of the Hong Kong Listing Rules allowing the listing of pre-revenue biotech companies in Hong Kong.
In the life science sector, May’s experience includes advising clients on negotiation of clinical trial agreements, preparation of a medical monitor agreement for the engagement of medical professionals in connection with Phase I clinical trial monitoring, acquisition of medical equipment by hospitals and pre-IPO investments into biotech companies.
